I didn’t say herabeat was more expensive. I said
mayo’s previous study concluded that use the standard fetal doppler in the home was more expensive because it was difficult to use and required direction from nurses. The Herabeat trial was supposed to be the first step in proving that the doppler use at home was indeed economic. https://assets.researchsquare.com/files/rs-114143/v1/c03160aa-cde7-445a-82aa-89bee6cec4c9.pdf?c=1631863603
I am not concluding that the herabeat is inferior; but the results I have pointed you to imply that in that particular trial, the standard doppler was more reliable in finding FHR and easier to use. Of course there might be a reasonable explanation for the results, but the company have swept it under the carpet. I was assured that the company would address this six months ago.
- Forums
- ASX - By Stock
- Why no news from joondalup and us?
I didn’t say herabeat was more expensive. I said mayo’s previous...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add HMD (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.181M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
HMD (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
Previous Video
Next Video
SPONSORED BY The Market Online